In COVID-19 clinical update #72, Daniel Griffin covers long term symptoms in children, outcomes for MIS-C, recent guidance from the American Academy of Pediatrics, a large well traced outbreak of delta variant, low dose mRNA vaccination generates durable T cell memory and antibodies, protective immunity in recovered patients, assessment of BinaxNOW, no effect of oral azithromycin, post-discharge symptoms in Nigeria, and therapeutics for low and middle income countries.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Long COVID in children (JAMA)
• Outcomes after MIS-C (Pediatrics)
• Guidance for school opening (Amer Acad Ped)
• Infection in well traced delta outbreak (medRxiv)
• Immune memory 8 months post-infection (Science)
• Low dose mRNA vaccine enhances T cells (medRxiv)
• Protection after infection (Lancet)
• Assessment of BinaxNOW (Sci Rep)
• Rapid POC antigen tests (Cochrane Rev)
• Oral azithromycin ineffective (JAMA)
• Post discharge symptoms in Nigeria (AJTMH)
• Therapeutics for low and middle income countries (AJTMH)
• Letters read on TWiV 783
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]